Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.

ABSTRACT:

Importance

ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC.

Objective

To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs.

Design, setting, and participants

A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excelle

SUBMITTER: Birkeland AC 

PROVIDER: S-EPMC4911238 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature